[go: up one dir, main page]

AR054385A1 - Inhibidores de la triazolopiridin -11- beta - hidroxiesteroide- deshidroogenasa tipo 1 - Google Patents

Inhibidores de la triazolopiridin -11- beta - hidroxiesteroide- deshidroogenasa tipo 1

Info

Publication number
AR054385A1
AR054385A1 ARP060102406A ARP060102406A AR054385A1 AR 054385 A1 AR054385 A1 AR 054385A1 AR P060102406 A ARP060102406 A AR P060102406A AR P060102406 A ARP060102406 A AR P060102406A AR 054385 A1 AR054385 A1 AR 054385A1
Authority
AR
Argentina
Prior art keywords
heteroaryl
aryl
heterocyclyl
alkyl
cycloalkyl
Prior art date
Application number
ARP060102406A
Other languages
English (en)
Inventor
James J Li
Haixia Wang
Lawrence G Hamann
Zheming Ruan
Christopher B Cooper
Jeffrey A Robi
Jun Li
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR054385A1 publication Critical patent/AR054385A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), los enantiomeros, los diastereoisomeros, solvatos, sales o profármacos de los mismos caracterizado porque: W es arilo, cicloalquilo, heteroarilo o heterociclilo, todos los cuales pueden estar opcionalmente sustituidos con R1, R1a, R1b, R1c y R1d; R1, R1a, R1b, R1c y R1d son independientemente H, halogeno, -OH, -CN, -NO2, -CO2R2a, -CONR2R2a, -SO2NR2R2a, -SOR2a, -SO2R2a, -NR2SO2R6, -NR2CO2R6, alquilo, haloalquilo, cicloalquilo, alcoxi, ariloxi, alquenilo, haloalcoxi, alquiltio, ariltio, arilsulfonilo, alquilamino, aminoalquilo, arilamino, heteroarilamino, arilo, heteroarilo o heterociclilo, en donde el grupo arilo, heteroarilo o heterociclilo puede estar opcionalmente sustituido con R7, R7a, R7b y R7c; o alternativamente cualesquiera dos de R1, R1a, R1b, R1c y R1d pueden ser tomados conjuntamente para formar un arilo fusionado, heteroarilo, anillo de heterociclilo o anillo de espiro-heterociclilo; L es un enlace, O, S, SO, SO2, alquenilo, cicloalquilo,. NR5, CR2R2a, CR2R2aCR2bR2c, SO2NR2, OCR2R2a, OCR2R2aCR2bR2c, CR2R2aO, CR2bR2cCR2R2aO, N(R5)CR2R2a, CR2R2aN(R5), SCR2R2a, CR2R2aS, CR2R2aSO, CR2R2aSO2, SOCR2R2a, SO2CR2R2a, CR2R2aOCR2bR2c, CR2R2aSCR2bR2c, CR2R2aSO2CR2bR2c, SO2NR2CR2aR2b, COCR2R2a, CR2R2aCO, CONR5CR2aR2b, CR2R2aCR2bR2cS, CR2R2aCR2bR2cSO, CR2R2aCR2bR2cSO2, con la condicion de que L no sea un enlace cuando W es fenilo, R2, R2a, R2b y R2c son independientemente H, halogeno, alquilo o haloalquilo; o alternativamente cualesquiera dos de R2, R2a, R2b y R2c pueden ser tomados conjuntamente con el átomo al cual están enlazados para formar un cicloalquilo, cicloalquilo sustituido con halogeno o anillo de heterociclilo; R3, R3a y R3b son independientemente H, halogeno, -OH, -CN, -NO2, -CO2R2a, -CONR2R2a, -SO2NR2R2a, -SOR2a, -SO2R2a, -NR2SO2R6, -NR2CO2R6, alquilo, haloalquilo, cicloalquilo, alcoxi, ariloxi, alquenilo, haloalcoxi, alquiltio, ariltio, arilsulfonilo, alquilamino, aminoalquilo, arilamino, heteroarilamino, arilo, heteroarilo o heterociclilo, donde el arilo, heteroarilo o el heterociclilo puede estar opcionalmente sustituido con R7, R7a, R7b y R7c; R4 es biciclo[2,2,2]octilo o biciclo[2,2,1]heptilo, los cuales pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados de halogeno, -OH, -OR6, -SR6, -OCOR6, -CN, -NR5COR6, -NR5SO2R6, -COR6, -CO2R6, -CO2H, -OCONR2R2a, -CONR2R2a, -NR5CO2R6, -SO2R6, alquilo, alcoxi, arilo, amino, heterociclilo o heteroarilo, en donde los grupos alquilo, alcoxi, arilo, heteroarilo o heterociclilo pueden estar opcionalmente sustituidos con R7, R7a, R7b, y R7c; o R4 es cicloalquilo, diferente de biciclo[2,2,2]octilo o biciclo[2,2,1]heptilo, los cuales pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados de halogeno, -OH, -OR6, -SR6, -OCOR6, -CN, -NR5COR6, -NR5SO2R6, -COR6, -CO2R6, -CO2H, -OCONR2R2a, -CONR2R2a, - NR5CO2R6, -SO2R6, alquilo, alcoxi, arilo, amino, heterociclilo o heteroarilo, en donde los grupos alquilo, alcoxi, arilo, heteroarilo o heterociclilo pueden estar opcionalmente sustituidos con R7, R7a, R7b, y R7c; o R4 es heterociclilo, los cuales pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados de halogeno, -OH, -OR6, -SR6, -OCOR6, -CN, -NR5COR6, -NR5SO2R6, -COR6, -CO2R6, -CO2H, -OCONR2R2a, -CONR2R2a, -NR5CO2R6, -SO2R6, alquilo, alcoxi, arilo, amino, heterociclilo o heteroarilo, en donde los grupos alquilo, alcoxi, arilo, heteroarilo o heterociclilo pueden estar opcionalmente sustituidos con R7, R7a, R7b, y R7c; R5 en cada aparicion, es independientemente , alquilo, cicloalquilo, arilo, haloalquilo, COR2a, CO2R2a, SO2NR2R2a o SO2R2a; R6 n cada aparicion, e independientemente alquilo, cicloalquilo, arilo o heteroarilo, todos los cuales pueden estar opcionalmente sustituidos con R7, R7a, R7b y R7c; y R7, R7a, R7b, y R7c, en cada aparicion, son independientemente halo, alquilo, haloalquilo, alcoxi, arilo, ariloxi, arilarilo, arilalquilo, arilalquiloxi, alquenilo, cicloalquilo, cicloalquilalquilo, cicloalquilalquiloxi, amino, -OH, hidroxialquilo, acilo, heteroarilo, heteroariloxi, heteroarilalquilo, heteroarilalcoxi, ariloxialquilo, alquiltio, arilalquiltio, ariloxiarilo, alquilamido, alcanoilamino, arilcarbonilamino, -NO2, -CN o tiol.
ARP060102406A 2005-06-09 2006-06-08 Inhibidores de la triazolopiridin -11- beta - hidroxiesteroide- deshidroogenasa tipo 1 AR054385A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68899305P 2005-06-09 2005-06-09
US11/448,947 US7579360B2 (en) 2005-06-09 2006-06-07 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

Publications (1)

Publication Number Publication Date
AR054385A1 true AR054385A1 (es) 2007-06-20

Family

ID=37574243

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102406A AR054385A1 (es) 2005-06-09 2006-06-08 Inhibidores de la triazolopiridin -11- beta - hidroxiesteroide- deshidroogenasa tipo 1

Country Status (26)

Country Link
US (2) US7579360B2 (es)
EP (1) EP1888582B1 (es)
JP (1) JP4994368B2 (es)
KR (1) KR20080019276A (es)
CN (1) CN102558176A (es)
AR (1) AR054385A1 (es)
AT (1) ATE487717T1 (es)
AU (1) AU2006257924B2 (es)
BR (1) BRPI0611773A2 (es)
CA (1) CA2611529C (es)
CY (1) CY1111148T1 (es)
DE (1) DE602006018135D1 (es)
DK (1) DK1888582T3 (es)
EA (1) EA013017B1 (es)
GE (1) GEP20105073B (es)
HR (1) HRP20110073T1 (es)
IL (1) IL187812A (es)
MX (1) MX2007015285A (es)
NO (1) NO20076055L (es)
NZ (1) NZ563457A (es)
PE (1) PE20070164A1 (es)
PL (1) PL1888582T3 (es)
PT (1) PT1888582E (es)
SI (1) SI1888582T1 (es)
TW (1) TW200716111A (es)
WO (1) WO2006135795A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TWI475995B (zh) 2007-09-14 2015-03-11 Janssen Pharmaceuticals Inc １’，３’－二取代－４－苯基－３，４，５，６－四氫－２ｈ，１’ｈ－〔１，４’〕聯吡啶基－２’－酮化物
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
JP5433579B2 (ja) 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン
US8119658B2 (en) * 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
AU2008323287B2 (en) 2007-11-14 2011-07-14 Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2417135A1 (en) 2009-04-07 2012-02-15 Schering Corporation Substituted triazolopyridines and analogs thereof
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
BR112012003973A2 (pt) 2009-08-26 2015-09-08 Sanofi Sa hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015061272A1 (en) 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015097121A1 (en) 2013-12-23 2015-07-02 Norgine B.V. Compounds useful as ccr9 modulators
EP3424535A1 (en) 2014-01-21 2019-01-09 Janssen Pharmaceutica NV Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
US9580420B2 (en) 2014-08-06 2017-02-28 Bristol-Meyers Squibb Company Process for the preparation of 4-(8-(2-chlorophenoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)bicyclo[2.2.1]heptan-1-ol and novel intermediates therefor
MX373154B (es) 2015-04-03 2020-04-22 Incyte Holdings Corp Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
UA125559C2 (uk) 2016-04-22 2022-04-20 Інсайт Корпорейшн Композиції інгібітора lsd1
CN109906224B (zh) * 2016-06-20 2022-02-25 诺华股份有限公司 三唑吡啶化合物及其应用
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3597423A (en) * 1966-08-31 1971-08-03 Boehringer Mannheim Gmbh 5-nitrofuryl-2-s-triazolo-(4,3-a)-pyridine derivatives
US4358453A (en) * 1982-01-08 1982-11-09 Schering Corporation 1,2,4-Triazolo[4,3-a]pyridines
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
RU2278114C2 (ru) 1999-04-28 2006-06-20 Др.Редди З Лабораториз Лимитед Замещенные бициклические гетероциклические соединения, способ их получения (варианты) и применение в качестве средств против ожирения и гиперхолестеринемии
JP2000319277A (ja) 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
JP4747396B2 (ja) 2000-05-17 2011-08-17 日立化成工業株式会社 接着剤組成物、それを用いた回路端子の接続方法及び回路端子の接続構造
OA12552A (en) * 2001-03-09 2006-06-06 Pfizer Prod Inc Triazolopyridines as anti-inflammatory agents.
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
JP2006508914A (ja) * 2002-08-30 2006-03-16 ファイザー・プロダクツ・インク トリアゾロ−ピリジン製造のための新規な方法および中間体
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
WO2004072072A1 (en) * 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
WO2004089380A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of fused 1,2,4-triazoles
WO2004107863A1 (en) * 2003-05-05 2004-12-16 Neurogen Corporation Sustituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands
JP4499106B2 (ja) 2003-05-29 2010-07-07 メルク・シャープ・エンド・ドーム・コーポレイション １１−ベータ−水酸化ステロイド脱水素酵素−１の阻害剤としてのトリアゾール誘導体
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
GB0325745D0 (en) 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
GB0326029D0 (en) 2003-11-07 2003-12-10 Astrazeneca Ab Chemical compounds
CN1910161A (zh) 2004-01-26 2007-02-07 默克公司 1型11－β－羟基甾醇脱氢酶抑制剂的新晶型
US7306631B2 (en) * 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US20080051409A1 (en) 2004-08-02 2008-02-28 Peter Gmeiner Indolizine Carboxamides and Aza and Diaza Derivatives Thereof
HRP20080608T3 (hr) * 2004-08-12 2008-12-31 Pfizer Inc. Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze
EP1781655A2 (en) 2004-08-18 2007-05-09 Pharmacia & Upjohn Company LLC Triazolopyridine compounds useful for the treatment of inflammation
BRPI0514327A (pt) 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos triazolopiridina
CA2583428A1 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
EP1790641A4 (en) 2004-09-16 2009-08-26 Astellas Pharma Inc DERIVATIVE OF TRIAZOLE OR SALT OF SAID DERIVATIVE
WO2006036816A2 (en) 2004-09-24 2006-04-06 Smithkline Beecham Corporation Chemical compounds
US20080261970A1 (en) 2004-09-27 2008-10-23 Elixir Pharmaceuticals, Inc. Sufonamides and Uses Thereof
BRPI0515931A (pt) 2004-09-29 2008-08-12 Hoffmann La Roche compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
MX2007004179A (es) 2004-10-07 2007-06-07 Warner Lambert Co Derivados de triazolpiridina como agentes antibacterianos.
WO2006038738A1 (ja) 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited 受容体機能調節剤
ATE384723T1 (de) 2004-10-13 2008-02-15 Merck Patent Gmbh Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
CA2584170C (en) 2004-10-13 2013-08-20 Wolfgang Staehle Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
ES2326827T3 (es) 2004-10-19 2009-10-20 Smithkline Beecham (Cork) Limited Anatagonistas del receptor de crf y metodos relacionados.
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
WO2006047631A2 (en) 2004-10-25 2006-05-04 University Of Medicine And Dentistry Of New Jersey Anti-mitotic anti-proliferative compounds
DK1807072T3 (da) 2004-10-29 2009-03-16 Lilly Co Eli Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1666467A1 (en) 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
ES2330872T3 (es) 2004-12-01 2009-12-16 Merck Serono Sa Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas.
WO2006080533A1 (ja) 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. ３－アミノ－１,２,４－トリアゾール誘導体
JPWO2007007688A1 (ja) 2005-07-08 2009-01-29 持田製薬株式会社 ３，５−ジアミノ−１，２，４−トリアゾール誘導体
CA2644963A1 (en) 2006-03-31 2007-10-11 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US8148396B2 (en) 2012-04-03
US7579360B2 (en) 2009-08-25
AU2006257924A1 (en) 2006-12-21
CA2611529C (en) 2013-12-03
KR20080019276A (ko) 2008-03-03
ATE487717T1 (de) 2010-11-15
JP4994368B2 (ja) 2012-08-08
JP2008543776A (ja) 2008-12-04
DE602006018135D1 (de) 2010-12-23
PE20070164A1 (es) 2007-03-11
IL187812A0 (en) 2008-08-07
PT1888582E (pt) 2011-01-14
EA200800006A1 (ru) 2008-06-30
CN102558176A (zh) 2012-07-11
WO2006135795A1 (en) 2006-12-21
CY1111148T1 (el) 2015-06-11
NO20076055L (no) 2008-03-05
GEP20105073B (en) 2010-09-10
EP1888582A1 (en) 2008-02-20
EP1888582B1 (en) 2010-11-10
TW200716111A (en) 2007-05-01
US20090203668A1 (en) 2009-08-13
PL1888582T3 (pl) 2011-05-31
CA2611529A1 (en) 2006-12-21
DK1888582T3 (da) 2011-02-28
AU2006257924B2 (en) 2012-03-08
HRP20110073T1 (hr) 2011-02-28
MX2007015285A (es) 2008-02-22
US20060287357A1 (en) 2006-12-21
EA013017B1 (ru) 2010-02-26
HK1112463A1 (en) 2008-09-05
SI1888582T1 (sl) 2011-03-31
BRPI0611773A2 (pt) 2010-09-28
NZ563457A (en) 2010-06-25
IL187812A (en) 2012-02-29

Similar Documents

Publication Publication Date Title
AR054385A1 (es) Inhibidores de la triazolopiridin -11- beta - hidroxiesteroide- deshidroogenasa tipo 1
AR057357A1 (es) Heterociclos nitrogenados como inhibidores de heteroaril 11-beta hidroxiesteroide deshidrogenasa tipo 1. composiciones farmaceuticas
AR068601A1 (es) Triazolopiridinas como inhibidores de 11- beta hidroxiesteroide tipo i
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
AR022283A1 (es) Aminas substituidas de espirofuropiridinas novedosas utiles en terapia
PE20070527A1 (es) Derivados de espirocromanona como agentes inhibidores de la acetil coenzima a carboxilasa
DK1098649T3 (da) Fremgangsmåde til stabilisering af farmaceutiske sammensætninger med speciel anvendelse af antioxidant
PE20050652A1 (es) Mezclas que contienen estrobilurinas y moduladores de etileno
ECSP045218A (es) "novedosos inhibidores de la gamma secretasa"
AR036093A1 (es) Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios
ATE535836T1 (de) Verfahren und einrichtungen zur verhinderung der neigung eines spiegels in einem interferometrischen modulator
DE59805727D1 (de) Thiazolderivate, verfahren zur herstellung und verwendung
ATE515277T1 (de) Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten
AR012781A1 (es) Alfa-cetoamida inhibidores de 20s proteosoma.
AR049483A1 (es) Combinacion de herbicidas
AR020551A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos.
CO5031247A1 (es) Compuestos triciclicos sustituidos
AR078461A1 (es) Inhibidores macrociclicos de la replicacion de virus de la hepatitis c
AR074691A1 (es) Derivados de tiazol como ligandos de receptores de cannabinoides
AR060385A1 (es) Compuestos organicos y sus usos
CO5080791A1 (es) Derivados de la piperidina que tienen efectos sobre sistemas con serotonina
ATE444251T1 (de) Mitnehmerkettenvorrichtung, lasche zur verwendung dafür und verfahren zur befestigung von laschen an gewünschten stellen entlang einer beweglichen endloskette
CO5261507A1 (es) Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos
CO4700460A1 (es) 5,6-DIHIDRO-9H-PIRAZOL[3,4-c]-1,2,4-TRIAZOL[4,3-a] PIRIDINAS TRICICLICAS
AR047981A1 (es) Inhibidores de caspasa y sus usos correspondientes

Legal Events

Date Code Title Description
FB Suspension of granting procedure